EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of intrapericardial administration after catheter drainage on malignant pericardial effusion in non‐small cell lung cancer: A real‐world study

Jingwen Wei iD, Zheng Shi iD, Zhengbo Song iD

Cancer Medicine · 2023

DOI: 10.1002/cam4.6404 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Jingwen Wei und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Trial, The Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Pericardial Effusion, Antineoplastic Agents, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Scientific Research Foundation of Zhejiang Province, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Malignant pericardial effusion (MPE) is a serious complication of cancer that can be potentially deadly. It usually occurs in advanced or terminal stages of the disease, and as a result, patients with MPE often have a poor prognosis. There is a limited amount of research available that directly compares the effectiveness and safety of intrapericardial drug administration following pericardial drainage versus catheter drainage alone in non‐small cell lung cancer (NSCLC) patients who have MPE.

Methods

We retrospectively included 86 patients with NSCLC with MPE at Zhejiang Cancer Hospital. Survival and recurrence estimates were determined with the Kaplan–Meier method.

Results

We divided the 86 patients with NSCLC into two groups: a pericardial drainage group (34 out of 86, 39.5%) and an intrapericardial administration group (52 out of 86, 60.5%). The response rates were 70.6% and 76.9% ( p = 0.510), respectively. The median OS was 132.0 and 234.0 days ( p = 0.579), respectively. The median time to recurrent drainage was 43.0 and 104.0 days ( p = 0.170), respectively. The incidence of adverse events (AEs) was 44.1% and 61.5% ( p = 0.113), respectively. The most frequent AEs were pain (27.9%) and fever (24.4%). Additionally, two patients in the intrapericardial administration group died of cardiac arrest.

Conclusions

Compared with catheter drainage alone, intrapericardial medication infusion during catheter drainage did not have significantly different effects. AEs require close monitoring and management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungPericardial EffusionAntineoplastic AgentsLung NeoplasmsCardiac TamponadePleural NeoplasmsHumansRetrospective StudiesCathetersDrainage

Stichwörter der Autor:innen

catheter drainageintrapericardial administrationmalignant pericardial effusionnon-small cell lung cancer

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Clinical Trial, The Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
  • Postgraduate training base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, China.

ORCID-Profile: Jingwen Wei, Zheng Shi, Zhengbo Song

Förderung

  • Medical Scientific Research Foundation of Zhejiang Province, China

Zitieren

APA

Wei, J., Shi, Z., & Song, Z. (2023). Effects of intrapericardial administration after catheter drainage on malignant pericardial effusion in non‐small cell lung cancer: A real‐world study. Cancer Medicine. https://doi.org/10.1002/cam4.6404

Vancouver

Wei J, Shi Z, Song Z. Effects of intrapericardial administration after catheter drainage on malignant pericardial effusion in non‐small cell lung cancer: A real‐world study. Cancer Medicine. 2023. doi:10.1002/cam4.6404

BibTeX
@article{Wei2023,
  author = {Wei, Jingwen and Shi, Zheng and Song, Zhengbo},
  title = {Effects of intrapericardial administration after catheter drainage on malignant pericardial effusion in non‐small cell lung cancer: A real‐world study},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6404}
}
Kostenlos starten →